Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A investigator initiated clinical study for QRX003 Netherton Syndrome (NS)

Next Previous
X
Search
Trial Profile

A investigator initiated clinical study for QRX003 Netherton Syndrome (NS)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 25 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QRX 003 (Primary)
  • Indications Netherton Syndrome
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 25 Dec 2024 New trial record
    • 19 Dec 2024 According to a Quoin Pharmaceuticals media release, the FDA has given clearance to conduct this study. The study will be conducted by Dr. Amy Paller, of Northwestern University. It is anticipated that the data generated from this study will be used to supplement the data package to support the potential regulatory approval of QRX003 as a treatment for NS.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top